Received Aug 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | DL4YY | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | KR75K | — |
Extra dose administered/2nd dose administered of Boostrix and Menveo; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 13-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number KR75K) for prophylaxis. Co-suspect products included Men ACWY-CRM NVS (Menveo) (batch number DL4YY) for prophylaxis. Previously administered products included Boostrix (received first dose of Boostrix on 19 Aug 2024) and Menveo (received first dose of Menveo on 19 Aug 2024). On 12-JUN-2025, the patient received the 2nd dose of Boostrix and the 2nd dose of Menveo. On 12-JUN-2025, an unknown time after receiving Boostrix and Menveo, the patient experienced extra dose administered (Verbatim: Extra dose administered/2nd dose administered of Boostrix and Menveo). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-JUL-2025 The patient did receive Boostrix and then Menveo when they were 12 years old, they came back at 13 years old, and they received it again which led to extra dose administered. During the call, the healthcare professional mentioned that the patient received for first time the Boostrix and Menveo on 19 Aug 2024. And the patient received again Boostrix and Menveo (1 vial) on 12 Jun 2025. The healthcare professional mentioned that for the 1st Menveo dose, they were not sure if this was the 1-vial or the 2-vials presentation and the 2nd Menveo dose was the 1-vial presentation.